Market Overview
The Australia pharmaceutical market size was valued at USD 25.3 Billion in 2025 and is projected to reach USD 31.9 Billion by 2034, exhibiting a CAGR of 2.57%. The market is driven by factors including a rapidly growing geriatric population, increasing chronic diseases, government healthcare funding through programs like the Pharmaceutical Benefits Scheme (PBS), rising demand for generic medicines, expansion of telehealth and e-pharmacy services, and heightened emphasis on preventive healthcare. This expansive growth fosters innovations in biopharmaceuticals and enhanced access to medications nationwide.
How AI is Reshaping the Future of Australia Pharmaceutical Market:
- AI integration accelerates drug discovery and precision medicine development, enhancing treatment options for complex diseases such as oncology and autoimmune disorders, supported by Australia’s advanced research infrastructure.
- Digital health platforms powered by AI streamline telehealth and e-pharmacy services, improving accessibility in remote areas and meeting the rising demand for pharmaceutical products.
- AI-driven analytics optimize patient adherence programs and product lifecycle management, helping pharmaceutical companies tailor treatments and improve health outcomes.
- Government initiatives increasingly support AI adoption in healthcare, with regulatory bodies like the Therapeutic Goods Administration (TGA) facilitating faster approvals of AI-enabled therapies.
- Pharmaceutical companies leverage AI for competitive intelligence and supply chain optimization, ensuring innovative and cost-effective drug delivery aligned with increasing demand for generics and biosimilars.
- Collaboration between biotech firms and AI-focused startups promotes development of novel drug delivery platforms, exemplified by commercial agreements for innovative treatments targeting unmet medical needs like pancreatic cancer.
Grab a sample PDF of this report: https://www.imarcgroup.com/australia-pharmaceutical-market/requestsample
Market Growth Factors
The Australian government plays a pivotal role in supporting pharmaceutical market growth through programs such as the Pharmaceutical Benefits Scheme (PBS), which allocates a public budget of AUD 43 billion for FY2023-24. This scheme subsidizes essential medicines, making healthcare more affordable and accessible, thus driving demand across demographics. Regulatory systems like the Therapeutic Goods Administration (TGA) ensure product safety while fostering innovation. The government’s commitment extends to funding healthcare infrastructure, research, and clinical trial investments, creating a robust environment for pharmaceutical companies to innovate and introduce new therapies.
Australia’s ageing population is a critical growth driver for the pharmaceutical industry. With males’ life expectancy at 81.1 years and females’ at 85.1 years during 2021-2023, the elderly population is expanding rapidly. For example, the number of Australians aged 85 and above is expected to grow from approximately 534,000 in 2021 to about 1,500,000 by 2041. This demographic shift results in increased prevalence of chronic diseases such as arthritis, cardiovascular diseases, and dementia, thereby elevating the demand for medications, including preventive and long-term care products tailored for older adults.
The pharmaceutical market is also benefiting from the expanding telehealth and e-pharmacy services across Australia. In 2022 and 2023, telehealth utilization included 20% of general practitioners and 11% of specialists, facilitating easier access to medical consultations and prescriptions. The swift rise in online prescription orders from e-pharmacies accelerates pharmaceutical distribution, especially in remote areas. This technological adoption enhances convenience for patients while transforming healthcare delivery, fueling market growth with increased pharmaceutical consumption tied to digital health innovations.
Market Segmentation
Analysis by Therapeutic Class:
- Alimentary Tract and Metabolism
- Blood and Blood Forming Organs
- Cardiovascular System
- Dermatologicals
- Genito Urinary System and Sex Hormones
- Systemic Hormonal Preparations
- Anti-infectives for Systemic Use
- Antineoplastic and Immunomodulating Agents
- Musculoskeletal System
- Nervous System
- Antiparasitic Products, Insecticides, and Repellents
- Respiratory System
- Sensory Organs
- Others
Analysis by Drug Type:
- Branded
- Generic
Analysis by Prescription Type:
- Prescription Drugs (Rx)
- OTC Drugs
Regional Analysis:
- Australia Capital Territory & New South Wales
- Victoria & Tasmania
- Queensland
- Northern Territory & Southern Australia
- Western Australia
Key Players
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca
- CSL Limited
- Eli Lilly Australia Pty Ltd
- GSK plc
- Merck KGaA
- Novartis Pharmaceuticals Australia Pty Ltd.
- Pfizer Australia Pty Ltd.
- Roche Australia
- Sanofi
Recent Development & News
- December 2024: Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals completed selling the Rare Pediatric Disease Priority Review Voucher issued by the US FDA for DAYBUE (trofinetide). Neuren will receive one-third of the revenues, supporting innovation and continued developmental funding.
- December 2024: Australian biotech Cartherics secured a US$300,000 G-Rex grant to enable clinical production of CTH-401 for upcoming trials, exemplifying expansion in clinical research infrastructure and government-industry collaboration.
- November 2024: Race Oncology concluded a drug development program targeting m6A RNA demethylase protein FTO using fragment-based NMR screening, identifying 39 candidate molecules for novel therapeutics, advancing cancer treatment innovation within the market.
Note: If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
Speak to an analyst for customized report sample: https://www.imarcgroup.com/request?type=report&id=21978&flag=C
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201-971-6302
Recent Comments